Bladder cancer is one of the ten most common cancers worldwide that can afflict both genders and is the 13th most common cause of death associated with cancer. A mixture of immunotherapy (BCG vaccine), chemotherapies, and surgery are currently used to treat bladder cancer. The management of early-stage bladder cancer contributes to a significant healthcare burden due to the high risk of recurrence, frequent monitoring of the disease, and high treatment costs.
Using primary research conducted with U.S. and European bladder cancer medical oncologists who have expertise treating bladder cancer, this report provides a comprehensive analysis of the competitive landscape and market opportunities for bladder cancer. This report includes an analysis of patient populations, current therapies and medical practices, unmet needs, and emerging therapies. Of currently approved therapies for treating bladder cancer, only valrubicin (Endo’s Valstar) and vinflunine (Pierre Fabre’s Javlor) do not yet face generic competition, even though valrubicin is no longer patent protected.
Questions Answered in This Report:
- The bladder cancer population will continue to grow as a reflection of an aging population. The growth will, however, be slightly counteracted by a decrease in the prevalence of smoking in the population. What is the size of U.S. and EU5 (France, Germany, Italy, Spain, and the UK) bladder cancer populations, and how will they change over the ten-year forecast period? What are the key bladder cancer drug-treatable patient populations?
- While surgery and adjuvant/ neoadjuvant chemotherapy are the basis for treatment of earlier stages of bladder cancer, advanced and metastatic disease is treated with chemotherapy. What type of practitioner assumes care of bladder cancer patients and how does it differ depending on the stage of the disease and/or the geographical market? How are physicians currently managing treatment of bladder cancer patients?
- There are several different drug classes in later-stage clinical development for bladder cancer, such as immunotherapies, angiogenesis inhibitors, cytotoxic agents, and heat shock protein inhibitors. What do experts interviewed think about the prospects of these emerging therapies? Which agents, if any, do we forecast will launch for the treatment of bladder cancer and how, if at all, will these launches impact the bladder cancer landscape?
- We have identified several unmet needs, challenges, and opportunities in the bladder cancer landscape. What are the key unmet needs in the treatment of bladder cancer according to interviewed thought leaders? Is it likely that these unmet needs will be addressed or partially addressed during our forecast period?
Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.
Primary research: Eight country-specific interviews with thought leaders (medical oncologists).
Epidemiology: Diagnosed incident cases of bladder cancer by stage of disease. Clinical- and market-relevant drug-treatable populations.
Population segments in market forecast: Non-muscle-invasive bladder cancer (low risk, intermediate risk, and high risk), muscle-invasive bladder cancer, treatment-naive stage IV N/M1+ bladder cancer, and pretreated stage IV N/1+ bladder cancer.
Emerging therapies: Phase II: 3 drugs; Phase III: 9 drugs.
Izabela Ammermann, Ph.D.
Michael Hughes, Ph.D.